WO2012050874A3 - Targeting heme for the treatment of immune mediated inflammatory diseases - Google Patents

Targeting heme for the treatment of immune mediated inflammatory diseases Download PDF

Info

Publication number
WO2012050874A3
WO2012050874A3 PCT/US2011/053634 US2011053634W WO2012050874A3 WO 2012050874 A3 WO2012050874 A3 WO 2012050874A3 US 2011053634 W US2011053634 W US 2011053634W WO 2012050874 A3 WO2012050874 A3 WO 2012050874A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
heme
inflammatory diseases
mediated inflammatory
immune mediated
Prior art date
Application number
PCT/US2011/053634
Other languages
French (fr)
Other versions
WO2012050874A2 (en
Inventor
Miguel P. Soares
Bernat Olle
Original Assignee
Soares Miguel P
Bernat Olle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soares Miguel P, Bernat Olle filed Critical Soares Miguel P
Publication of WO2012050874A2 publication Critical patent/WO2012050874A2/en
Publication of WO2012050874A3 publication Critical patent/WO2012050874A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to methods of limiting the deleterious effects of free heme for the treatment of inflammatory and infectious pathologies, including administration of heme scavengers such as human hemoproteins, and to methods for the diagnosis, prognosis, stratification, and monitoring of diseases associated with free heme- mediated pathological damage.
PCT/US2011/053634 2010-09-28 2011-09-28 Targeting heme for the treatment of immune mediated inflammatory diseases WO2012050874A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38739510P 2010-09-28 2010-09-28
US61/387,395 2010-09-28

Publications (2)

Publication Number Publication Date
WO2012050874A2 WO2012050874A2 (en) 2012-04-19
WO2012050874A3 true WO2012050874A3 (en) 2012-06-07

Family

ID=45938862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053634 WO2012050874A2 (en) 2010-09-28 2011-09-28 Targeting heme for the treatment of immune mediated inflammatory diseases

Country Status (1)

Country Link
WO (1) WO2012050874A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7121057B2 (en) 2013-05-21 2022-08-17 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Engineered heme-binding constructs and uses thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
KR102125695B1 (en) * 2012-10-03 2020-06-24 체에스엘 베링 아게 A method of purifying proteins
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
EP3912986B1 (en) 2013-12-18 2023-12-13 President and Fellows of Harvard College Crp capture/detection of bacteria
KR101795115B1 (en) * 2014-02-03 2017-11-08 최원형 Anti-tuberculosis composition for treating or preventing tuberculosis comprising gamma-Linolenic acid
TW201629215A (en) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 Compositions and methods for treatment with hemopexin
CN108289928A (en) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 Improved microorganism-binding molecule and its purposes
KR101810295B1 (en) * 2015-09-06 2017-12-18 최원형 Anti-tuberculosis composition for treating or preventing tuberculosis comprising Artemisinin
WO2018005759A1 (en) * 2016-07-01 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
US20200237652A1 (en) 2017-08-08 2020-07-30 Csl Behring Ag Hemopexin formulations
CN111100119B (en) * 2019-12-25 2022-06-24 湖南大学 Reactive free heme specific response small-molecule fluorescent probe and synthesis method and application thereof
CN111012771A (en) * 2020-01-08 2020-04-17 辽宁大学 Application of ferulic acid in preparation of medicine for inhibiting chromium-induced lung inflammatory injury
CN112843030A (en) * 2020-09-08 2021-05-28 天津国际生物医药联合研究院 Potential application of flunarizine or fluoxetine in resisting mycobacterium infection
CN112691098A (en) * 2021-02-20 2021-04-23 首都医科大学附属北京中医医院 Application of ferulic acid in preparation of medicine for treating sepsis intestinal mucosa barrier function damage

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013623A (en) * 1997-02-27 2000-01-11 The Trustees Of Columbia University In The City Of New York Use of heme-peptides to prevent or retard disease associated with oxidative stress
US20070269537A1 (en) * 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
US20080171021A1 (en) * 2002-06-21 2008-07-17 Beth Israel Deaconess Medical Center, Inc. Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
US20080293623A1 (en) * 2007-04-30 2008-11-27 Nhs Blood And Transplant Enriched haptoglobin polymers for the treatment of disease
US20090149383A1 (en) * 2007-12-07 2009-06-11 University Of Washington Compositions and methods for facilitating heme-iron export from cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013623A (en) * 1997-02-27 2000-01-11 The Trustees Of Columbia University In The City Of New York Use of heme-peptides to prevent or retard disease associated with oxidative stress
US20080171021A1 (en) * 2002-06-21 2008-07-17 Beth Israel Deaconess Medical Center, Inc. Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
US20070269537A1 (en) * 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
US20080293623A1 (en) * 2007-04-30 2008-11-27 Nhs Blood And Transplant Enriched haptoglobin polymers for the treatment of disease
US20090149383A1 (en) * 2007-12-07 2009-06-11 University Of Washington Compositions and methods for facilitating heme-iron export from cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7121057B2 (en) 2013-05-21 2022-08-17 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Engineered heme-binding constructs and uses thereof

Also Published As

Publication number Publication date
WO2012050874A2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
WO2012050874A3 (en) Targeting heme for the treatment of immune mediated inflammatory diseases
IL238869A0 (en) Compositions and methods for treating neoplasia, inflammatory disease and other disorders
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
MY158992A (en) Forms of rifaximin and uses thereof
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
WO2012129341A3 (en) Disease detection in plants
WO2010151640A3 (en) Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
MX2013004061A (en) Cyclosporin analogs.
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
WO2014151456A3 (en) Treatment of inflammatory diseases
EP2529033A4 (en) Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders
WO2012087160A3 (en) Anti-inflammatory proteins and methods of preparation and use thereof
WO2013007596A3 (en) Oral treatment of inflammatory bowel disease
WO2013106273A3 (en) Peptides and methods of using same
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EP2852570A4 (en) Compositions and methods for the treatment of inflammatory bowel disease
WO2012065153A3 (en) Modified immune-modulating particles
MX2013004062A (en) Cyclosporin analogs.
WO2013169631A3 (en) Wnt protein signalling inhibitors
WO2015080980A3 (en) Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11833034

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11833034

Country of ref document: EP

Kind code of ref document: A2